Last updated: March 22, 2026
What is the drug associated with NDC 42799-0115?
NDC 42799-0115 corresponds to Remdesivir (Veklury), an antiviral medication approved by the FDA for the treatment of COVID-19 in hospitalized patients requiring supplemental oxygen, ventilation, or extracorporeal membrane oxygenation.
Market Overview
Current Market Position
Remdesivir has maintained a significant role in COVID-19 treatment protocols globally since its emergency use authorization (EUA) in May 2020, with full FDA approval granted in October 2020. Its market share is influenced by evolving treatment guidelines, competing therapies, and manufacturing capacity.
Key Market Players
- Gilead Sciences: Manufacturer, sole supplier.
- Governments and health agencies: Major purchasers due to stockpiling and distribution programs.
- Competing therapies: Oral antivirals like Paxlovid (Pfizer) and molnupiravir (Merck).
Regulatory Landscape
Post-approval, Gilead's pricing has been subject to negotiations with government agencies and payers. The drug's distribution is primarily through hospital channels and centralized procurement programs.
Global Market Demand Trends
Demand remains driven by COVID-19 case incidence, which fluctuates seasonally and geographically. Future demand projections depend on pandemic trajectory, emerging variants, and vaccination rates.
Price Dynamics and Projections
Historical Pricing Data
Initially, Gilead set the Wholesale Acquisition Cost (WAC) at approximately $520 per vial in the U.S. for a five-day treatment course, totaling around $2,200 per patient. Over time, discounting and negotiations resulted in lower prices for government contracts.
| Year |
Approximate WAC per Vial |
Treatment Course Cost (5-day) |
Notes |
| 2020 |
$520 |
$2,200 |
Initial launch price |
| 2021 |
<$300 (via negotiations) |
$1,320 |
Discounting for government and institutional buyers |
| 2022 |
~$300 |
~$1,300 |
Price stabilization, negotiated discounts |
Note: Exact prices vary depending on procurement terms, volume discounts, and region.
Future Price Projections
Based on market factors, supply and demand, and internal pricing strategies:
- Short-term (next 12 months): Price is expected to remain stable around $300-$350 per vial, considering negotiated discounts and supply chain stability.
- Medium-term (1-3 years): Price may decline slightly to $250-$300 per vial if competition increases or if biosimilar manufacturing begins. Despite the lack of biosimilar development for remdesivir, comparable healthcare budget pressures could drive further discounts.
- Long-term (beyond 3 years): Price trends depend on patent expiration, biosimilar entry, or therapeutic replacement. If biosimilars enter the market, prices could fall to $150-$200 per vial.
Factors Influencing Price Trajectory
- Patent protection: Gilead's patents prevent biosimilar competition until at least 2030.
- Manufacturing capacity: Gilead can scale production to meet global demand, potentially stabilizing prices.
- Regulatory approvals: Expanded indications or new formulations could alter pricing.
- Market competition: Emergence of oral antivirals reduces reliance on remdesivir, pressuring prices downward.
- Government negotiations: Bulk purchasing agreements can significantly reduce prices in large markets.
Market Size and Revenue Projections
Estimating total revenue involves multiplying projected quantities by unit prices:
| Year |
Estimated Global Usage (courses) |
Estimated Revenue (USD millions) |
| 2023 |
15 million courses |
$4.5 billion |
| 2024 |
10-12 million courses |
$3.5 billion |
| 2025 |
8-10 million courses |
$2.5 billion |
Assumptions:
- Global demand declines as vaccination rates increase and COVID-19 becomes endemic.
- Pricing remains within the projected range.
- Access distribution strategies evolve to include lower-income markets.
Competitive and Regulatory Risks
- The entry of cheaper biosimilars could substantially reduce prices.
- Changes in treatment guidelines eroding remdesivir's market share.
- Political and health policy shifts could influence procurement strategies and reimbursement levels.
Key Takeaways
- Remdesivir (NDC 42799-0115) remains a significant COVID-19 therapeutic in the short term.
- Prices have declined from initial launch but are expected to stabilize around $300 per vial in the near term.
- Long-term price decline hinges on biosimilar entry, patent expirations, and the evolution of COVID-19 treatment strategies.
- Market demand is expected to decrease as vaccination coverage improves and alternative therapies gain prominence.
- Stakeholders should monitor regulatory developments and supply chain dynamics impacting pricing and availability.
FAQs
-
Will remdesivir prices fall further in the next year?
Yes, if negotiated discounts continue and supply increases, prices are likely to stabilize or decline marginally.
-
Are biosimilars expected for remdesivir?
Currently, no biosimilars are in development or approved, largely due to patent protections and the complexity of manufacturing.
-
How does remdesivir compete with oral antivirals?
Oral antivirals like Paxlovid and molnupiravir offer ease of administration and are increasingly recommended for outpatient use, reducing remdesivir’s market share.
-
What impact do government procurement programs have on pricing?
Bulk procurement and strategic stockpiling, particularly by the U.S. government, have led to negotiated discounts, influencing market prices.
-
Could future COVID-19 variants affect remdesivir’s market?
Yes, if new variants reduce remdesivir’s efficacy or alter clinical guidelines, demand could decline further.
References
[1] Gilead Sciences. (2022). Veklury (remdesivir) package insert.
[2] U.S. Food and Drug Administration. (2020). FDA approves remdesivir for treatment of COVID-19.
[3] IQVIA. (2022). Global Healthcare Market Trends Report.
[4] Pharma Intelligence. (2023). COVID-19 Therapeutics Market Analysis.
[5] World Health Organization. (2023). COVID-19 Treatment Guidelines.
